4-Aminopyrrolidine-2,4-dicarboxylic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-Aminopyrrolidine-2,4-dicarboxylic acid
• 化学式: C₆H₁₀N₂O₄
• mdl: MFCD24390560
• 分子量: 174.15
• InChiKey: XZFMJVJDSYRWDQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -6.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  113
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• Pyrrolidinyl di-carboxylic acid derivatives as metabotropic glutamate receptor antagonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP0703218A1

  公开（公告）日：1996-03-27

  The present invention provides pyrrolidinyl di-carboxylic acid derivatives that affect certain excitatory amino acid receptors, and are useful in the treatment of neurological disorders and psychiatric disorders. This invention further provides novel pyrrolidinyl di-carboxylic acid derivatives and pharmaceutical formulations employing these novel compounds.

  本发明提供了影响特定兴奋性氨基酸受体的吡咯烷二羧酸衍生物，并且在治疗神经系统疾病和精神疾病方面具有用途。本发明还提供了新型的吡咯烷二羧酸衍生物和使用这些新化合物的药物配方。
• Trans Pyrrolidinyl Derivates and Their Pharmaceutical Use
  申请人：Schann Stephan

  公开号：US20080027127A1

  公开（公告）日：2008-01-31

  The present invention relates to the use of trans pyrrolidinyl of the formula (I) or (II) in which: R 1 , R 2 or R 3 are hydrogen or a carboxy or amino protecting group; R 4 to R 8 represent hydrogen or an alkyl radical; R 9 represents a (R 10 ) n (—R 11 ) m group wherein R 10 is —CO—, —CS—, —O—, —S—, —SO—, —SO 2 —, —COO—, —CONR a —, —N(R a )CO—, —CSNR a —, —N(R a )CS—, —N(R a )—, R b , aryl, and R 11 is a polar group, for the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals.

  本发明涉及使用式（I）或（II）的反式吡咯烷基，其中：R1、R2或R3为氢或羧基或氨基保护基；R4至R8表示氢或烷基基团；R9表示（R10）n（—R11）m基团，其中R10为—CO—、—CS—、—O—、—S—、—SO—、—SO2—、—COO—、—CONRa—、—N（Ra）CO—、—CSNRa—、—N（Ra）CS—、—N（Ra）—、Rb、芳基，而R11为极性基团，用于治疗和/或预防与改变谷氨酸能信号和/或功能相关的疾病和/或可以受到哺乳动物谷氨酸水平或信号改变影响的疾病。
• CIS pyrrolidinyl derivatives and their uses
  申请人：Faust Pharmaceuticals

  公开号：EP1604977A1

  公开（公告）日：2005-12-14

  The present invention provides new cis pyrrolidinyl of the formula (I) or (II) in which: R1, R2 or R3 are hydrogen or a carboxy or amino protecting group; R4 to R8 represent hydrogen or an alkyl radical; R9 represents a (R10)n(-R11)m group wherein R10 is -CO-, -CS-, -O-,-S-, -SO-, -SO2-, -COO-, -CON(Cn'H2n'+1)-, -N(Cn'H2n'+1)CO-, -CSN(Cn'H2n'+1)- ,-N(Cn'H2n'+1)CS-, -N(Cn'H2n'+1)-, -(Cn'H2n'+1)-, aryl, and R11 is a polar group, and to their use for the treatment and/or prophylaxis of a condition associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling

  本发明提供了式 (I) 或 (II) 的新顺式吡咯烷基 其中 R1、R2 或 R3 是氢或羧基或氨基保护基；R4 至 R8 代表氢或烷基；R9 代表 (R10)n(-R11)m 基团，其中 R10 是 -CO-、-CS-、-O-、-S-、-SO-、-SO2-、-COO-、-CON(Cn'H2n'+1)-、-N(Cn'H2n'+1)CO-、-CSN(Cn'H2n'+1)-、-N(Cn'H2n'+1)CS-、-N(Cn'H2n'+1)-、-(Cn'H2n'+1)-、芳基，且 R11 为极性基团、 以及它们用于治疗和/或预防与谷氨酸能信号和/或功能改变相关的疾病，和/或可受谷氨酸水平或信号改变影响的疾病
• Trans pyrrolidinyl derivatives and their pharmaceutical uses
  申请人：Faust Pharmaceuticals

  公开号：EP1604978A1

  公开（公告）日：2005-12-14

  The present invention relates to the use of trans pyrrolidinyl of the formula (I) or (II) in which: R1, R2 or R3 are hydrogen or a carboxy or amino protecting group; R4 to R8 represent hydrogen or an alkyl radical; R9 represents a (R10)n(-R11)m group wherein R10 is -CO-, -CS-, -O-, -S-, -SO-, -SO2-, -COO-, -CON(Cn'H2n'+1)-,-N(Cn'H2n'+1)CO-, -CSN(Cn'H2n'+1)-, -N(Cn'H2n'+1)CS-, -N(Cn'H2n'+1)-, -(Cn'H2n'+1)-, aryl, and R11 is a polar group, for the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals.

  本发明涉及式 (I) 或 (II) 的反式吡咯烷基的用途 其中 R1、R2 或 R3 是氢或羧基或氨基保护基；R4 至 R8 代表氢或烷基；R9 代表 (R10)n(-R11)m 基团，其中 R10 是 -CO-、-CS-、-O-、-S-、-SO-、-SO2-、-COO-、-CON(Cn'H2n'+1)-、-N(Cn'H2n'+1)CO-、-CSN(Cn'H2n'+1)-、-N(Cn'H2n'+1)CS-、-N(Cn'H2n'+1)-、-(Cn'H2n'+1)-、芳基，而 R11 是极性基团、 用于治疗和/或预防与谷氨酸能信号和/或功能改变相关的疾病，和/或可受哺乳动物体内谷氨酸水平或信号改变影响的疾病。
• Bis (amino acid) molecular scaffolds
  申请人：——

  公开号：US20040082783A1

  公开（公告）日：2004-04-29

  The present invention provides molecular building blocks of rigid bis(amino acids). The molecular building blocks can be linked together through the formation of rigid diketopiperazine rings, to provide oligomers having the desired three dimensional structure. Oligomers formed from the basic building blocks are also disclosed.

  本发明提供了刚性双（氨基酸）分子构件。通过形成刚性二酮哌嗪环，分子构筑模块可以连接在一起，从而提供具有所需三维结构的低聚物。本发明还公开了由基本构筑模块形成的低聚物。